Table 1 Patient characteristics
Summary statistics | |
|---|---|
n = 3384 | |
Demographics | |
Age at enrolment (years), median [IQR] (range) | 39 [30, 50] (17,87) |
Age at diagnosis (years), median [IQR] (range) | 29 [21, 39] (1, 84) |
Disease duration at enrolment (years), median [IQR] (range) | 8 [3, 15] (0, 51) |
Study duration (years), median [IQR] (range) | 2.4 [0.4, 4.3] (0, 7) |
Total visits, median [IQR] (range) | 7 [2, 12] (1, 81) |
Female, n (%) | 3109 (92) |
Family history of SLE, n (%) | 249 (7.9) |
Asian ethnicity, n (%) | 2868 (87.4) |
Current smoker at enrolment, n (%) | 162 (5.1) |
Tertiary education, n (%) | 1482 (49.1) |
Serological profile at enrolment, n (%) | |
ANA positivity | 2939 (87.5) |
Anti-dsDNA positivity | 2430 (72.4) |
Low complement | 2116 (63.0) |
Medication use-ever (at least once), n (%) | |
Prednisolone (PNL) use | 2765 (81.7) |
TAM-prednisolone (mg/day), median [IQR] (range) | 5.0 [2.2, 9.1] (0, 50) |
Anti-malarial (AM) use | 2577 (76.2) |
Immunosuppressant (IS) use | 1751 (51.7) |
Biological use | 35 (1.03) |
Clinical profile across the follow-up period | |
LLDAS ever, n (%) | 2529 (75.7) |
LLDAS never, n (%) | 813 (24.3) |
Percent time spent in LLDAS, median [IQR] (range) | 45.8 [8.4, 73.8] (0, 100) |
TAM-PGA, median [IQR] (range) | 0.43 [0.22, 0.75] (0, 3) |
AMS, median [IQR] (range) | 3.0 [1.4, 4.8] (0, 22) |
AMS > 4, n (%) | 932 (33.8) |
High Disease Activity State (HDAS; SLEDAI ≥ 10) ever, n (%) | 851 (25.1) |
Any flare (mild/moderate/severe) ever, n (%) | 1762 (52.1) |
Organ damage present at recruitment, n (%) | 1165 (37.9) |
Damage accrual during the study period, n (%) | 561 (18.3) |
Deaths, n (%) | 58 (1.7) |
No. of patients with at least one SF36 survey, n (%) | 2,583 (76.3) |
TAM-SF36 (PCS), median [IQR] (range) | 49.2 [43.7, 53.5] (19.7, 62.3) |
TAM-SF36 (MCS), median [IQR] (range) | 49.2 [42.6, 53.7] (18.8, 63.7) |